Skip to content

Patient experience and advocacy in uterine adenosarcoma

TL;DR — There is no adenosarcoma-specific qualitative study. The closest formal study interviewed 13 patients with mixed uterine-sarcoma histologies and 23 clinicians: physical themes were sexual dysfunction and urological symptoms; mental themes were fear of recurrence, shock of diagnosis, and lack of sarcoma knowledge (den Hollander 2022, PMID 35443673). One 2026 fertility-sparing case report includes a short narrative from a single patient about possible fertility loss and pregnancy after diagnosis; that is an n=1 perspective, not qualitative cohort evidence (Ziegler 2026, PMID 42334466). Patient organisations that cover this disease do so as uterine sarcoma or sarcoma in general; no adenosarcoma-only organisation was identified in searches rerun on 2026-09-01. There is no dedicated adenosarcoma trial, although mixed-histology uterine-sarcoma protocols have included the histology (clinical-trials landscape).

Coverage limit (read this first)

PubMed searches rerun on 2026-09-01 combining adenosarcoma with qualitative, lived experience, patient experience, patient reported, and quality-of-life terms did not return an adenosarcoma-specific qualitative study. The den Hollander mixed-methods paper is uterine sarcoma (13 patients, mixed histologies, NCT04071704) (den Hollander 2022, PMID 35443673). Ziegler’s 2026 adenosarcoma case report includes a short patient perspective but remains a single case (PMID 42334466). Themes below are reported as uterine-sarcoma-class findings unless a source is histology-specific.

Diagnosis journey

The clinical literature already documents the mislabel: recurrent “polyps” (Clement 1990, PMID 2156771), preoperative pathology that fails (Tate 2018, PMID 29441675), occult sarcoma among presumed fibroids (Raine-Bennett 2016, PMID 26646120; Multinu 2019, PMID 30447212). den Hollander’s interviewees described shock of diagnosis, the fibroid-to-sarcoma reversal, and “dealing with lacking knowledge regarding sarcoma” as HRQoL issues for patients and professionals (den Hollander 2022, PMID 35443673). Items on lack of sarcoma knowledge, shock of diagnosis, and menopausal symptoms were missing from EORTC QLQ-C30 and QLQ-EN24, which patients otherwise rated as relevant (den Hollander 2022, PMID 35443673).

NCI’s patient PDQ lists adenosarcoma among uterine sarcomas and lists abnormal bleeding, a vaginal mass, abdominal pain or fullness, and frequent urination as signs (NCI PDQ — "Uterine Sarcoma Treatment", https://www.cancer.gov/types/uterine/patient/uterine-sarcoma-treatment-pdq, accessed 2026-09-01). The previously cited American Cancer Society “questions to ask” URL now redirects to its general detection, diagnosis, and staging hub; the stale question-list claim has therefore been removed (ACS — "Early Detection, Diagnosis, and Staging of Uterine Sarcoma", https://www.cancer.org/cancer/types/uterine-sarcoma/detection-diagnosis-staging.html, accessed 2026-09-01).

What living with it involves (aggregate, mixed uterine sarcoma)

den Hollander 2022, 13 patients + 23 professionals, thematic analysis:

Domain Themes reported
Physical Sexual dysfunction; urological symptoms; hormone-related issues; gastrointestinal symptoms; fatigue; pain; treatment adverse effects
Mental Fear (of sex, of recurrence, of death); altered body image; lacking knowledge about sarcoma
Social Impact on relationships; limited activities; loss of independence; work/study capacity; financial difficulty

Most EORTC QLQ-C30 and QLQ-EN24 items were rated relevant; combining cancer-generic, location-specific and sarcoma-specific items was the authors’ measurement recommendation (den Hollander 2022, PMID 35443673). Sexual dysfunction after hysterectomy and iatrogenic menopause after BSO are the surgical-management correlates; they have not been quantified in an adenosarcoma-only cohort.

Fertility, age, and the young-patient minority

Adenosarcoma occurs from adolescence (Clement range 14–89, median 58; Yuan median 47.5) (Clement 1990, PMID 2156771; Yuan 2019, PMID 31139558). Fertility-sparing management is documented as case reports and a 7-patient stage IA subset (L’Heveder 2019, PMID 31584132; Yuan 2019, PMID 31139558). A 2026 case report adds one spontaneous term pregnancy after local resection of stage IA disease without sarcomatous overgrowth; follow-up through 2025 showed no recurrence (Ziegler 2026, PMID 42334466). Piątek’s mixed uterine-sarcoma fertility series of 11, including 3 adenosarcomas, noted that adenosarcoma patients “may have a low chance of childbearing” (Piątek 2022, PMID 36012998). These are case-level or very small mixed-histology data, and guidelines do not establish fertility-sparing as standard (Karabajakian 2023, PMID 37202293).

Trial ineligibility as a feature of the disease

No dedicated adenosarcoma randomised trial exists. Basket trials that name the histology (FUCHSia NCT03926936, n=17 total across several low-grade gyn cancers; elacestrant NCT07467772, estimated n=30 across four uterine-sarcoma subtypes) will enrol few, if any, adenosarcomas per year. DART (NCT02834013) does not name adenosarcoma as a cohort. Patients who ask about trials are being offered sarcoma-basket or uterine-sarcoma-basket slots, not an adenosarcoma programme. See clinical-trials landscape.

Organisations (audited 2026-09-01)

These organisations cover uterine sarcoma or sarcoma; none identified in the 2026-09-01 searches was adenosarcoma-specific. Details and access limitations live in literature/patient-voice/organizations.md.

Organisation What it offers this patient group URL / audit status
Foundation for Women’s Cancer Gyn-cancer education, research, and public awareness; works in partnership with SGO https://foundationforwomenscancer.org/ — accessed 2026-09-01
Sarcoma UK Support line (0808 801 0401), information, support, and research funding https://sarcoma.org.uk/ — accessed 2026-09-01
Sarcoma Foundation of America Directory entry retained, but service and funding claims were not independently re-verified https://curesarcoma.org/ — automated access returned HTTP 403 on 2026-09-01
Sarcoma Alliance Practical resources and assistance with the cost of an expert second opinion https://sarcomaalliance.org/ — accessed 2026-09-01
NCI Patient PDQ for uterine sarcoma, including adenosarcoma staging https://www.cancer.gov/types/uterine/patient/uterine-sarcoma-treatment-pdq — accessed 2026-09-01
American Cancer Society General uterine-sarcoma detection, staging, treatment, and survivorship information https://www.cancer.org/cancer/types/uterine-sarcoma/detection-diagnosis-staging.html — accessed 2026-09-01

Sarcoma UK signposts a Gynae Sarcoma email forum (groups.io) and an Endometrial Stromal Sarcoma Facebook group. Those are closed or semi-closed communities; their contents were not accessed (CONVENTIONS §3). Their existence is the finding.

Advocacy priorities that follow from the evidence, not from a patient-council vote

No adenosarcoma patient-council priority-setting exercise was retrieved. Priorities that the literature itself surfaces:

  1. Expert pathology review, specifically a comment on sarcomatous overgrowth, invasion and LVSI (Carroll 2014, PMID 25449308; Nathenson 2018, PMID 30044322).
  2. Avoiding morcellation of undiagnosed uterine masses (Raine-Bennett 2016, PMID 26646120; Ray-Coquard 2024, PMID 39322612).
  3. A rare-tumour consortium that can run an adjuvant question in stage I SO (Carroll 2014, PMID 25449308).
  4. HRQoL instruments that include sarcoma knowledge, diagnostic shock, and menopausal symptoms (den Hollander 2022, PMID 35443673).

Open questions

  • Do adenosarcoma patients’ HRQoL priorities differ from LMS (sexual/urological vs pain/metastasis) enough to need a histology-specific module? den Hollander cannot answer; n=13 mixed (PMID 35443673).
  • Searches of the verified sarcoma and gynaecologic-cancer organisations on 2026-09-01 found no public registry or organisation in which adenosarcoma patients were identifiable as a group; closed-community contents were not accessed.

References

  1. den Hollander D, et al. 'I thought I had fibroids, and now I don't': a mixed method study on health-related quality of life in uterine sarcoma patients. Health Qual Life Outcomes. 2022;20:65. PMID 35443673
  2. Clement PB, Scully RE. Mullerian adenosarcoma of the uterus: a clinicopathologic analysis of 100 cases. Hum Pathol. 1990;21:363-81. PMID 2156771
  3. Tate K, et al. Uterine adenosarcoma in Japan. Asia Pac J Clin Oncol. 2018;14:318-325. PMID 29441675
  4. Raine-Bennett T, et al. Occult Uterine Sarcoma and Leiomyosarcoma: Incidence of and Survival Associated With Morcellation. Obstet Gynecol. 2016;127:29-39. PMID 26646120
  5. Multinu F, et al. Incidence of sarcoma in patients undergoing hysterectomy for benign indications. Am J Obstet Gynecol. 2019;220:179.e1-179.e10. PMID 30447212
  6. Carroll A, et al. Uterine adenosarcoma: an analysis on management, outcomes, and risk factors for recurrence. Gynecol Oncol. 2014;135:455-61. PMID 25449308
  7. Nathenson MJ, et al. The Importance of Lymphovascular Invasion in Uterine Adenosarcomas. Int J Gynecol Cancer. 2018;28:1297-1310. PMID 30044322
  8. Yuan Z, et al. Uterine Adenosarcoma: A Retrospective 12-Year Single-Center Study. Front Oncol. 2019;9:237. PMID 31139558
  9. L'Heveder A, et al. Conservative management of uterine adenosarcoma: lessons learned from 20 years of follow-up. Arch Gynecol Obstet. 2019;300:1383-1389. PMID 31584132
  10. Piątek S, et al. Fertility-Sparing Management May Be Considered in Young Women with Uterine Sarcoma. J Clin Med. 2022;11:4761. PMID 36012998
  11. Karabajakian A, et al. Uterin adenosarcoma: French Guidelines. Bull Cancer. 2023;110:836-843. PMID 37202293
  12. Ray-Coquard I, et al. ESGO/EURACAN/GCIG guidelines for the management of patients with uterine sarcomas. Int J Gynecol Cancer. 2024;34:1499-1521. PMID 39322612
  13. Ziegler E, et al. Fertility-sparing strategy in a rare case of uterine adenosarcoma and consecutive spontaneous pregnancy and livebirth. Arch Gynecol Obstet. 2026. PMID 42334466